Logo image of MESO

MESOBLAST LTD- SPON ADR (MESO) Stock Fundamental Analysis

NASDAQ:MESO - Nasdaq - US5907174016 - ADR - Currency: USD

16.37  -0.86 (-4.99%)

After market: 16.3565 -0.01 (-0.08%)

Fundamental Rating

2

Overall MESO gets a fundamental rating of 2 out of 10. We evaluated MESO against 571 industry peers in the Biotechnology industry. Both the profitability and financial health of MESO have multiple concerns. MESO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MESO has reported negative net income.
MESO had a negative operating cash flow in the past year.
MESO had negative earnings in each of the past 5 years.
MESO had a negative operating cash flow in each of the past 5 years.
MESO Yearly Net Income VS EBIT VS OCF VS FCFMESO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With an excellent Return On Assets value of -13.14%, MESO belongs to the best of the industry, outperforming 85.92% of the companies in the same industry.
The Return On Equity of MESO (-18.31%) is better than 87.17% of its industry peers.
Industry RankSector Rank
ROA -13.14%
ROE -18.31%
ROIC N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
MESO Yearly ROA, ROE, ROICMESO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MESO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MESO Yearly Profit, Operating, Gross MarginsMESO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

MESO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MESO has more shares outstanding
Compared to 5 years ago, MESO has more shares outstanding
MESO has a worse debt/assets ratio than last year.
MESO Yearly Shares OutstandingMESO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MESO Yearly Total Debt VS Total AssetsMESO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 4.66 indicates that MESO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.66, MESO is in the better half of the industry, outperforming 79.86% of the companies in the same industry.
MESO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
MESO has a worse Debt to Equity ratio (0.21) than 71.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 4.66
ROIC/WACCN/A
WACC9.49%
MESO Yearly LT Debt VS Equity VS FCFMESO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 1.18 indicates that MESO should not have too much problems paying its short term obligations.
MESO's Current ratio of 1.18 is on the low side compared to the rest of the industry. MESO is outperformed by 85.74% of its industry peers.
MESO has a Quick Ratio of 1.18. This is a normal value and indicates that MESO is financially healthy and should not expect problems in meeting its short term obligations.
MESO has a Quick ratio of 1.18. This is amonst the worse of the industry: MESO underperforms 84.31% of its industry peers.
Industry RankSector Rank
Current Ratio 1.18
Quick Ratio 1.18
MESO Yearly Current Assets VS Current LiabilitesMESO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

MESO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.15%, which is quite good.
The Revenue for MESO has decreased by -21.32% in the past year. This is quite bad
Measured over the past years, MESO shows a very negative growth in Revenue. The Revenue has been decreasing by -18.80% on average per year.
EPS 1Y (TTM)15.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.08%
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%17.53%

3.2 Future

MESO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 58.68% yearly.
MESO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 158.01% yearly.
EPS Next Y1.6%
EPS Next 2Y16.2%
EPS Next 3Y40.47%
EPS Next 5Y58.68%
Revenue Next Year103.91%
Revenue Next 2Y218.88%
Revenue Next 3Y252.66%
Revenue Next 5Y158.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MESO Yearly Revenue VS EstimatesMESO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B
MESO Yearly EPS VS EstimatesMESO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MESO. In the last year negative earnings were reported.
Also next year MESO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MESO Price Earnings VS Forward Price EarningsMESO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MESO Per share dataMESO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

MESO's earnings are expected to grow with 40.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.2%
EPS Next 3Y40.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MESO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MESOBLAST LTD- SPON ADR

NASDAQ:MESO (2/21/2025, 8:00:01 PM)

After market: 16.3565 -0.01 (-0.08%)

16.37

-0.86 (-4.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20 2024-11-20/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners12.21%
Inst Owner Change-85.71%
Ins Owners18.53%
Ins Owner ChangeN/A
Market Cap2.08B
Analysts77.5
Price Target18.28 (11.67%)
Short Float %2.22%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)26.31%
PT rev (3m)64.56%
EPS NQ rev (1m)9.5%
EPS NQ rev (3m)10.09%
EPS NY rev (1m)12.84%
EPS NY rev (3m)13.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-7.12%
Revenue NY rev (3m)34.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 352.25
P/FCF N/A
P/OCF N/A
P/B 4.33
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-3.44
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS0.05
BVpS3.78
TBVpS-0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.14%
ROE -18.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.06%
ROA(5y)-12.61%
ROE(3y)-17.67%
ROE(5y)-16.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 4.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.18
Quick Ratio 1.18
Altman-Z 4.66
F-Score4
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.22%
Cap/Sales(5y)7.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-87.08%
EPS Next Y1.6%
EPS Next 2Y16.2%
EPS Next 3Y40.47%
EPS Next 5Y58.68%
Revenue 1Y (TTM)-21.32%
Revenue growth 3Y-7.5%
Revenue growth 5Y-18.8%
Sales Q2Q%17.53%
Revenue Next Year103.91%
Revenue Next 2Y218.88%
Revenue Next 3Y252.66%
Revenue Next 5Y158.01%
EBIT growth 1Y-6.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.2%
EBIT Next 3Y80.34%
EBIT Next 5YN/A
FCF growth 1Y23.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.41%
OCF growth 3YN/A
OCF growth 5YN/A